UPDATE: Ranbaxy’s generic of Novartis blockbuster Diovan approved for launch

Eric Palmer

The long-delayed and highly anticipated of is on the way, which is a bummer for and a huge boost for Indian drugmaker Ranbaxy Laboratories. It is also validation for the decision by Sun Pharmaceutical's owner, billionaire Dilip Shanghvi, who struck a $ 3.2 billion deal to buy Ranbaxy despite its years of FDA entanglements over quality issues.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS